WEBSITE BSE:544184 NSE: BOROSCI Inc. Year: 1991 Industry: Glass My Bucket: Add Stock
Last updated: 15:51
No Notes Added Yet
1. Business Overview
Borosil Scientific Ltd. (BOROSCI) is an Indian company that manufactures and distributes a diverse range of glass products. The company was demerged from Borosil Ltd. (now Borosil Renewables Ltd.) in December 2023, taking over its scientific & industrial products and consumer products businesses. Its core business revolves around two primary segments:
Scientific & Industrial Products (SIP): This segment includes laboratory glassware, scientific instruments, liquid handling products, filtration products, and primary pharma packaging (e.g., ampoules and vials). It caters primarily to research & development institutions, educational facilities, healthcare, and pharmaceutical companies.
Consumer Products: This segment focuses on borosilicate glassware for home and kitchen use, including cookware, bakeware, storage solutions, and serveware. It targets retail consumers.
The company generates revenue by manufacturing these products in its facilities across India and selling them through a wide network of distributors, retailers, and direct institutional sales.
2. Key Segments / Revenue Mix
Based on its latest financial reporting (e.g., FY24 results post-demerger):
Scientific & Industrial Products (SIP): Contributes approximately 65% of the total revenue. This segment is driven by B2B sales to various industries.
Consumer Products: Contributes approximately 35% of the total revenue. This segment is driven by B2C sales through retail channels.
3. Industry & Positioning
Borosil Scientific operates in specialized segments of the broader Indian glass industry.
Scientific Glassware: The company holds a dominant position as the undisputed market leader in laboratory glassware in India, facing competition from both domestic and international brands. The market is driven by healthcare, pharmaceutical, biotech, and educational sectors.
Borosilicate Consumer Glassware: Borosil Scientific is also a pioneer and market leader in the borosilicate consumer glassware category in India, known for its heat-resistant and durable kitchenware. It competes with other kitchenware brands, including those offering ceramics, plastics, and soda-lime glass, as well as a few other borosilicate glass manufacturers.
Pharma Packaging: This is a growing segment for the company, where it competes with other specialized glass packaging manufacturers.
The company's long-standing presence and specialized manufacturing capabilities give it a strong foothold in its core markets.
4. Competitive Advantage (Moat)
Borosil Scientific possesses several durable advantages:
Brand Strength: The "Borosil" brand enjoys very high recall and trust, particularly in the scientific community where it is almost synonymous with quality laboratory glassware in India. This strong brand equity also extends to its consumer borosilicate products.
Market Leadership & Scale: Being a market leader in both scientific and borosilicate consumer glassware provides economies of scale in manufacturing, procurement, and distribution.
Extensive Distribution Network: The company has a well-established and wide distribution network across India for both its institutional (scientific) and retail (consumer) products, which is challenging for new entrants to replicate.
Product Quality & Reliability: Borosil is known for its high-quality, durable borosilicate glass products, which fosters customer loyalty, especially in demanding applications like laboratories and kitchens.
5. Growth Drivers
Key factors that can drive Borosil Scientific's growth over the next 3-5 years include:
Increasing R&D and Healthcare Spending: Growth in India's pharmaceutical, biotechnology, and healthcare sectors (e.g., new hospitals, diagnostic labs, vaccine production) will directly fuel demand for laboratory glassware, scientific instruments, and pharma packaging.
"Make in India" Initiative: Government focus on domestic manufacturing and reducing import dependence for critical inputs (like pharma packaging and lab equipment) can benefit Borosil Scientific.
Premiumization in Consumer Segment: Rising disposable incomes and increasing consumer preference for healthier, durable, and safer borosilicate glass kitchenware over plastics or traditional glass products.
Geographic and Product Expansion: Opportunities to expand market reach within India and potentially in select international markets, along with introducing new value-added products in both scientific and consumer categories.
Focus on Pharma Packaging: The growth in the Indian pharmaceutical industry, especially injectables, presents a significant growth avenue for its primary pharma packaging business.
6. Risks
Key business risks for Borosil Scientific include:
Raw Material and Energy Price Volatility: The manufacturing process is energy-intensive and relies on raw materials like silica sand, soda ash, and other chemicals. Fluctuations in their prices can impact profitability.
Intense Competition: The company faces competition from established domestic players and international brands across all its segments, which can exert pressure on pricing and market share.
Economic Slowdown: A general economic downturn can lead to reduced consumer spending on discretionary items (consumer segment) and cutbacks in R&D budgets or healthcare investments (scientific segment).
Technological Changes: While less common for basic glassware, advancements in lab technology or new material sciences could potentially impact demand for traditional glass products in the long term.
Regulatory Changes: Especially in the pharmaceutical packaging segment, changes in quality standards, certifications, or import/export policies could pose challenges.
7. Management & Ownership
Borosil Scientific Ltd. is part of the Kheruka Group, with the Kheruka family being the promoters. The management team comprises experienced professionals with a deep understanding of the glass industry and a long history with the Borosil brand. As of March 31, 2024, the Promoter and Promoter Group held approximately 66.82% of the company's shares, indicating strong promoter commitment.
8. Outlook
Borosil Scientific holds a strong market position, especially in India's specialized labware and borosilicate consumer glassware segments. The company benefits from a powerful brand legacy, established distribution, and strong manufacturing capabilities. The increasing focus on healthcare, pharmaceutical R&D, and premiumization in consumer goods offers favorable growth tailwinds.
However, the company operates in a competitive environment and is exposed to raw material and energy price volatility. While its leadership position provides a buffer, sustained growth will depend on continuous innovation, efficient cost management, and effective expansion into new product lines like pharma packaging. The recent demerger has created a focused entity, but its success will hinge on efficient capital allocation and execution of its growth strategies in its standalone avatar.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹1057 Cr.
Stock P/E 39.5
P/B 2.6
Current Price ₹118.8
Book Value ₹ 45.2
Face Value 1
52W High ₹190.5
Dividend Yield 0%
52W Low ₹ 96.7
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 92 | 100 | 116 | 105 | 103 | 101 | 129 | 96 | 107 | 121 |
| Other Income | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 2 | 2 |
| Total Income | 93 | 101 | 117 | 106 | 105 | 103 | 132 | 99 | 109 | 124 |
| Total Expenditure | 83 | 88 | 97 | 94 | 87 | 91 | 113 | 91 | 99 | 104 |
| Operating Profit | 11 | 13 | 20 | 12 | 17 | 12 | 19 | 8 | 10 | 20 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7 | 0 | -2 |
| Profit Before Tax | 6 | 8 | 15 | 7 | 12 | 7 | 14 | -4 | 5 | 13 |
| Provision for Tax | 1 | 2 | 5 | 2 | 4 | 3 | 5 | 0 | 2 | 4 |
| Profit After Tax | 5 | 6 | 9 | 5 | 9 | 4 | 9 | -4 | 3 | 9 |
| Adjustments | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 |
| Profit After Adjustments | 5 | 6 | 9 | 5 | 9 | 4 | 9 | -4 | 3 | 9 |
| Adjusted Earnings Per Share | 0.6 | 0.6 | 1 | 0.6 | 1 | 0.5 | 1 | -0.5 | 0.3 | 1 |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Net Sales | 396 | 438 | 453 |
| Other Income | 4 | 8 | 10 |
| Total Income | 400 | 446 | 464 |
| Total Expenditure | 349 | 386 | 407 |
| Operating Profit | 51 | 60 | 57 |
| Interest | 3 | 2 | 0 |
| Depreciation | 16 | 18 | 20 |
| Exceptional Income / Expenses | 0 | 0 | -9 |
| Profit Before Tax | 32 | 40 | 28 |
| Provision for Tax | 8 | 14 | 11 |
| Profit After Tax | 23 | 27 | 17 |
| Adjustments | 0 | 0 | 0 |
| Profit After Adjustments | 24 | 27 | 17 |
| Adjusted Earnings Per Share | 2.7 | 3 | 1.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 11% | 0% | 0% | 0% |
| Operating Profit CAGR | 18% | 0% | 0% | 0% |
| PAT CAGR | 17% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -16% | NA% | NA% | NA% |
| ROE Average | 7% | 7% | 7% | 7% |
| ROCE Average | 11% | 10% | 10% | 10% |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Shareholder's Funds | 376 | 404 |
| Minority's Interest | 0 | 0 |
| Borrowings | 4 | 2 |
| Other Non-Current Liabilities | 8 | 11 |
| Total Current Liabilities | 100 | 87 |
| Total Liabilities | 488 | 504 |
| Fixed Assets | 192 | 187 |
| Other Non-Current Assets | 6 | 7 |
| Total Current Assets | 291 | 310 |
| Total Assets | 488 | 504 |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Opening Cash & Cash Equivalents | 1 | 12 |
| Cash Flow from Operating Activities | 30 | 120 |
| Cash Flow from Investing Activities | -2 | -115 |
| Cash Flow from Financing Activities | -16 | -3 |
| Net Cash Inflow / Outflow | 12 | 1 |
| Closing Cash & Cash Equivalent | 12 | 13 |
| # | Mar 2024 | Mar 2025 |
|---|---|---|
| Earnings Per Share (Rs) | 2.65 | 3.01 |
| CEPS(Rs) | 4.5 | 5.08 |
| DPS(Rs) | 0 | 0 |
| Book NAV/Share(Rs) | 41.1 | 44.2 |
| Core EBITDA Margin(%) | 11.79 | 11.99 |
| EBIT Margin(%) | 8.65 | 9.56 |
| Pre Tax Margin(%) | 7.97 | 9.21 |
| PAT Margin (%) | 5.93 | 6.09 |
| Cash Profit Margin (%) | 10.08 | 10.31 |
| ROA(%) | 4.81 | 5.38 |
| ROE(%) | 6.43 | 7.05 |
| ROCE(%) | 8.98 | 10.63 |
| Receivable days | 56.67 | 54.96 |
| Inventory Days | 89.28 | 80.49 |
| Payable days | 101.74 | 84.92 |
| PER(x) | 0 | 40.53 |
| Price/Book(x) | 0 | 2.76 |
| Dividend Yield(%) | 0 | 0 |
| EV/Net Sales(x) | 0.03 | 2.48 |
| EV/Core EBITDA(x) | 0.23 | 17.97 |
| Net Sales Growth(%) | 0 | 10.73 |
| EBIT Growth(%) | 0 | 22.43 |
| PAT Growth(%) | 0 | 13.81 |
| EPS Growth(%) | 0 | 13.6 |
| Debt/Equity(x) | 0.05 | 0.04 |
| Current Ratio(x) | 2.91 | 3.56 |
| Quick Ratio(x) | 1.94 | 2.45 |
| Interest Cover(x) | 12.68 | 27.13 |
| Total Debt/Mcap(x) | 0 | 0.01 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 67.92 | 67.87 | 67.84 | 67.82 | 67.81 | 67.81 | 67.81 | 68.08 |
| FII | 0.38 | 0.37 | 0.26 | 0.24 | 0.21 | 0.07 | 0.07 | 0.09 |
| DII | 0.15 | 0.02 | 0.02 | 0.02 | 0.05 | 0.1 | 0.19 | 0.26 |
| Public | 31.55 | 31.74 | 31.88 | 31.92 | 31.94 | 32.03 | 31.94 | 31.58 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.03 | 6.06 |
| FII | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| DII | 0.01 | 0 | 0 | 0 | 0 | 0.01 | 0.02 | 0.02 |
| Public | 2.8 | 2.82 | 2.83 | 2.84 | 2.84 | 2.85 | 2.84 | 2.81 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8.88 | 8.89 | 8.89 | 8.89 | 8.89 | 8.89 | 8.89 | 8.89 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.